Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Sygnis Pharma AG. (3/4/13). "Press Release: Sygnis Pharma AG Secures Further Financial Resources with Shareholder Loan". Heidelberg.

Organisations Organisation Sygnis Pharma AG
  Today Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Expedeon (Group)
  Organisation 2 Dievini Hopp BioTech Holding GmbH & Co. KG
  Group HOPP Group (family of Dietmar Hopp)
  Index term 2 Genetrix (ES)–Sygnis: investment, 201207–201212 acquisition of X-Pol by Sygnis via reverse merger w X-Pol holding 77.5% of Sygnis after closing
Person Person Willinger, Peter (Apogenix 201506– CFO before Sygnis Pharma + Lion Bioscience)

SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today reports on the granting of a shareholder loan for a total amount of up to EUR 0.7 million by its main shareholders Genetrix Life Sciences, A.B., Uppsala (Sweden) and dievini Hopp BioTech holding GmbH & Co. KG, Walldorf (Germany) with an interestrate at customary market conditions. As a result this loan, which is payable on demand and subject to a condition precedent, secures the financing of SYGNIS' existing operations, according to the present plans, until mid 2013. The loan is unsecured and is due for repayment not before the end of 2015.

**** end of ad hoc ****

For further information please contact:

Peter Willinger
Tel: +49 6221 454 836

### Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany,, Tel: +49-6221-454-6, Fax: +49-6221-454-700

Record changed: 2017-04-02


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Expedeon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top